Guido Lancman is a clinical associate at the Princess Margaret Cancer
Centre and adjunct Assistant Professor in the Department of Medicine at the
University of Toronto. Prior to coming to Toronto, he obtained his M.D. at the
Icahn School of Medicine at Mount Sinai in New York, and his M.Sc. in Clinical
Trials with distinction at University College London in the UK. He completed
his Internship and Residency in Internal Medicine, as well as his Fellowship in
Hematology and Medical Oncology at Mount Sinai. Dr. Lancman was involved in
research throughout his training, receiving the Mount Sinai Summer Research
Scholars Award in medical school, the SOHO Young Investigator Travel Award
in residency, and obtaining funding for two investigator-initiated studies
during his fellowship. His research has focused on optimizing the efficacy
and safety of novel therapies in multiple myeloma, with a particular interest in
immunotherapies. He is involved in the development of multiple myeloma
clinical trials through Princess Margaret and through the Canadian Myeloma
 Research Group